4DMedical progresses to a commercial agreement with Qscan

Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces the signing of a commercial contract with Qscan Radiology Clinics ("Qscan"), a leading provider of diagnostic imaging services in Queensland. This agreement follows a successful pilot of 4DMedical’s products with Qscan, and represents the first Australian contract to incorporate products from both the Pulmonary Function and Pulmonary Structure suites, including CT LVAS™.

Pilot success leads to commercial agreement

With 40 clinics across Queensland, New South Wales, ACT, Tasmania, and Western Australia, Qscan is one of Australia’s leading medical imaging providers, offering a comprehensive range of diagnostic and interventional radiology services.

Following the success of a pilot program, which demonstrated the clinical and operational effectiveness of 4DMedical’s proprietary suite of products, 4DMedical and Qscan have entered a commercial arrangement under which Qscan will offer 4DMedical’s respiratory imaging solutions at select practices in Brisbane.

This agreement marks 4DMedical’s first Australian commercial contract to incorporate products from both its Pulmonary Function and Pulmonary Structure suites. Specifically, the agreement with Qscan will provide clinicians with access to CT LVAS™, Lung Density Analysis™ - Inspiration (LDAi), Functional Lung Density Analysis™ (LDAf), and Lung Texture Analysis™ (LTA), each providing advanced diagnostic capabilities to support referrers and patients.

Reports will be delivered and billed on a Software-as-a-Service model on terms in line with those of the Company’s other commercial partners.

4DMedical MD/CEO and Founder Andreas Fouras said:

Having completed our pilot with Qscan, we are excited to have progressed to a commercial agreement. This partnership ensures that more patients and clinicians have access to detailed, actionable insights into lung health, supporting better healthcare outcomes.

Momentum continues to build with the commercialisation of our technology across the US and Australia. With the addition of Qscan to our network of providers in Australia, I am excited to see our footprint expand to ensure our cutting-edge technology is now becoming more readily available to all Australians.

Click here for the full ASX Release

This article includes content from 4DMedical, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.